The article presents the rationale, clinical development, and current status of poly (ADP ribose) polymerase inhibitors (PARPis) as anticancer agents.
INTRODUCTION
Cellular DNA damage must be repaired to preserve the integrity of the human genome. DNA damage can present as single-strand breaks (SSBs), doublestrand breaks, or stalling of the replication fork [1] . Multiple pathways and mechanisms are involved in DNA damage repair (DDR), including the base excision repair (BER), nucleotide excision repair, singlestrand annealing, mismatch repair as well as homologous recombination (HR) and nonhomologous end joining [2] pathways. The poly (ADP ribose) polymerase (PARP) superfamily of enzymes plays a crucial role in DDR, controlling both enzymatically and structurally the mechanism of BER to repair SSBs [3] . Following PARP inhibition, SSBs progress to double-strand breaks because of the collapse of the replication fork, requiring either HR or nonhomologous end joining pathways for repair [4 && ]. The superfamily of PARP proteins is a branch of ADP-ribosyltransferases that are activated by DNA damage, and include 17 enzymes of which PARP-1 is the most abundant and best described [5,6 & ]. PARP enzymes are recruited to DNA damage sites, and after binding to these undergo ADP-ribosylation together with histones H1/H2B leading to uncoiling of chromatin and permitting DNA repair with consumption of nicotinamide adenine dinucleotide (NADþ) and release of nicotinamide [1, 7] . PARP inhibitors (PARPis) have been reported to inhibit the catalytic activity of PARP-1, and hypothesized to potentiate the effect of chemotherapeutic agents because of the accumulation of SSBs from delayed DDR [8] . PARPis are also postulated to enable 'trapping' of PARP-1 and 2 at DNA repair sites, which precludes accessibility of other repair proteins and inhibits catalytic repair thus exerting their antitumor effect [1, 9] . Additionally, preclinical work suggests that trapped PARP-DNA complexes are cytotoxic in their own way, which may contribute to their mechanism of action [9] .
Cells carrying BRCA1 and 2 deleterious mutations were noted to have an increased sensitivity to cell death following treatment with PARPi [10] . In the presence of BRCA1 and 2 mutations, inhibition of BER pathway following administration of PARPi results in accumulation of unrepaired double-strand DNA breaks, leading to cell death, a phenomena referred to as 'synthetic lethality'. Defects in the HR pathway can also occur because of aberrations in genes other than the BRCA genes, referred to as 'BRCA-ness', such as mutations in ataxia telangiectasia mutated (ATM), RAD51, RAD54, CHK2, phosphatase and tensin homolog (PTEN), and PALB2 or because of epigenetic silencing of BRCA1 and 2 [2, 7, 11] . Presence of mutations or epigenetic changes resulting in defects in the HR pathway may also sensitize cells to PARP inhibition.
Granting of accelerated approval to the PARPi olaparib (Lymparza, AstraZeneca, Maryland, USA), by the US Food and Drug Administration (FDA) in December 2014 for the treatment of BRCA-defective advanced ovarian cancer further validates the modulation of the DDR pathway as a successful therapeutic strategy in the cancer armamentarium [12] . This approval was granted together with a companion in-vitro diagnostic test, BRACAnalysis CDX (Myriad Genetics, Inc., Utah, USA), to detect for the presence of germline mutations in the BRCA gene (gBRCAm), identified by PCR/Sanger sequencing of whole blood specimens.
Clinical experience with poly (ADP ribose) polymerase inhibitors: current inhibitors in development Currently, five PARPis are undergoing evaluation in cancer: olaparib, rucaparib, niraparib, veliparib, and talazoparib.
Olaparib
Given the preclinical data suggesting marked sensitivity of BRCA-deficient tumors to PARPi, a proof-ofconcept phase I clinical trial was performed to test olaparib (AZD2281, Ku-0059436, PARP1/2 IC 50 5 nM/1 nM [13] , AstraZeneca, London, UK) in patients with refractory solid tumors. The phase I clinical trial enriched its target population for gBRCAm 1 and 2, which was the main patient group to benefit from therapy (clinical benefit seen in 63% of gBRCAm 1/2 carriers). The maximum tolerated dose was identified at 400 mg twice daily (b.i.d.) by mouth, which was well tolerated with mild fatigue and gastrointestinal side-effects as the main toxicities [14] . An additional 50 ovarian cancer patients with gBRCAm 1/2 showed correlation between platinum sensitivity and PARP response (clinical benefit rate 69, 45, and 23% for the platinum-sensitive, resistant, and refractory groups, respectively) [15] .
Two separate phase II trials confirmed the efficacy and minimal toxicity of olaparib in patients with gBRCAm advanced breast and ovarian cancers, respectively, at an oral dose of 400 mg b.i.d. [16, 17] . A follow-up phase II trial evaluated olaparib as a treatment for high-grade serous ovarian cancer and triple-negative breast cancer (TNBC), with a reported 41% response rate in germline BRCA1/2 mutation (gBRCA1/2m) patients with ovarian cancer [18] . Olaparib was also compared with pegylated doxorubicin (PLD) in gBRCAm 1/2 platinum-resistant ovarian cancer. Median progression-free survival (PFS) was 6.5, 8.8, and 7.1 months for the olaparib 200 mg, olaparib 400 mg, and PLD groups, respectively. There was no difference in PFS [hazard ratio, 0.88; 95% confidence interval (CI), 0.51-1.56; P ¼ 0.66] for the combined olaparib doses vs. PLD [19] . There were also no differences in the response rate between patients treated with olaparib at a higher/lower dose and PLD. It is important to note that though this trial was negative, this well tolerated oral PARPi generated a similar outcome as intravenous chemotherapy [19] .
A placebo-controlled phase II maintenance trial was initiated in patients with high-grade serous ovarian cancer with or without gBRCAm. The PFS in this trial was 8.4 months for patients treated with olaparib 400 mg b.i.d. compared with 4.8 months for patients taking placebo. These results were not expected to translate into a significant overall survival benefit, and plans to continue development were tentatively shelved. This decision was reversed following a retrospective review of the trial, which revealed that patients carrying gBRCAm 1/2 showed an improvement in PFS (11.2 compared with 4.3 months) in favor of olaparib treatment [4 && ].
KEY POINTS
Olaparib, a first-in-class poly ADP PARPi, has been approved by the FDA for use in heavily pretreated, gBRCA1/2m ovarian cancer with a companion BRCA gene detection test.
PARPis, as monotherapy or in combination with other agents, are in advanced stages of clinical development for both wild-type and gBRCA1/2m tumors.
The combination of cediranib and olaparib has shown clinical activity in recurrent platinum-sensitive ovarian cancer.
Interestingly, accelerated approval was not granted for olaparib in the maintenance setting but rather as a single agent in patients with gBRCAm 1/2-associated ovarian cancer (three or more prior lines of therapy) based on the published results of the phase III SOLO2 trial, where 34% of patients had objective responses that lasted an average of 7.9 months [4 && ]. This approval is contingent on the results of the SOLO3 phase III trial (olaparib vs. physicians' treatment of choice); primary outcome is PFS.
Veliparib Veliparib (ABT-888, PARP1/2 IC 50 5.2 nM/2.9 nM [13] , AbbVie, Illinois, USA) is an oral PARP-1 and 2 inhibitors. The single-agent phase I/II study has been presented, with reported greater clinical activity in the gBRCAm patients compared with wild type (overall response rate ¼ 23% combining all dose levels: 50-500 mg b.i.d.) with a tolerable toxicity profile [20] . Veliparib has the broadest clinical development plan in combination trials at this time.
Rucaparib
This intravenous PARPi (PF-01367338, PARP1 IC 50 1.4 nM [13] , Clovis Oncology, Colorado, USA) was the first to enter clinical trials [6 & ,21] , though it has lagged behind in therapeutic development. Rucaparib was evaluated in combination with temozolomide in refractory solid tumors in a phase I setting [22] ; this same combination in the first-line setting for metastatic melanoma reported significant bone marrow toxicity [23] . Phase II trials are underway, including as a single agent in gBRCAm breast and ovarian cancer (ARIEL2, Table 1 ) and in the phase III ARIEL3 maintenance trial, where patients with or without gBRCAm 1/2 will be stratified according to HR status.
Niraparib Niraparib (MK-4827, PARP1/2 IC 50 3.2 nM/4.0 nM [13] , Tesaro, Massachusetts, USA) is a selective PARP-1/2 inhibitor, currently available in an oral formulation, which is being evaluated in phase II trials either as a single agent or in combination with standard of care chemotherapy in advanced solid tumors [2] . Niraparib has also entered phase III trial evaluation, NOVA, to determine its clinical activity as a single agent in the maintenance setting for gBRCAm 1/2 or sporadic platinum-sensitive recurrent ovarian cancer [4 && ].
Talazoparib Talazoparib (BMN 673, PARP1/2 IC 50 1.2 nM/0.9 nM [13] , BioMarin, California, USA) is currently undergoing both single and combination clinical trials and is being evaluated in phase I, II, and III trials to date (Table 1) . Talazoparib is a selective PARP-1/2 inhibitor that has been reported to have antitumor effects at lower concentrations than other inhibitors [8] . Since myelosuppression was the dose-limiting toxicity in the single-agent trial, there was concern about the feasibility of safely administering the combination of talazaparib with full-dose cytotoxic chemotherapy. Preclinical data support the antitumor benefit of combining low-dose chemotherapy with talazoparib [8] . Phase I trials in pediatric and adult patients are ongoing with results awaited.
COMBINATION TREATMENT STRATEGIES WITH POLY (ADP RIBOSE) POLYMERASE INHIBITORS
Poly (ADP ribose) polymerase inhibitors in combination: chemotherapy and radiation
Preclinically, the combination of PARP inhibitors with cytotoxic chemotherapy has been shown to potentiate DNA damage by inhibiting ongoing repair; however, this is associated with an increase in the toxicity of the combination compared with single-agent chemotherapy. Chemotherapy agents that induce SSBs, such as temozolomide and topoisomerase inhibitors, have been previously evaluated in combination with PARPi; however, it is the combination with platinum agents that has shown the most significant antitumor activity [5] . This is postulated to be secondary to platinum agents inducing DNA crosslinks, which are usually repaired by HR or BER. A phase I study of olaparib, cisplatin, and gemcitabine in solid tumors reported grade 4 myelosuppression at the first dose level, and needed deescalation to determine the maximum tolerated dose [24] . Veliparib in combination with topotecan administered over 5 days was also associated with significant myelosuppression, limiting the doses of veliparib that could be safely administered [25] . However, the combination was better tolerated when topotecan was administered weekly along with veliparib, with veliparib successfully given at doses !200 mg b.i.d. [26] . However, various encouraging, and effective, veliparib combination trials have been presented or reported in 2015. Promising preliminary results have been reported in combination with irinotecan [27] and along with carboplatin/paclitaxel [28] in patients with TNBC. Preliminary phase I results of veliparib in combination with intravenous and intraperitoneal paclitaxel/cisplatin AE bevacizumab in the adjuvant setting have achieved safe recommended phase II dose of veliparib at 150 mg b.i.d. [29] . In a phase I study of irinotecan and veliparib with an expansion cohort in TNBC patients, 7/8 BRCA mutation patients had partial response and 7/10 non-BRCA mutation patients had stable disease [27] . Veliparib in combination with temozolomide is being evaluated in the ongoing precision medicine trial Molecular Profiling-based Assignment of Cancer Therapy, for the treatment of patients carrying genetic defects in the DNA repair pathway, other than gBRCAm. The medicine trial will explore the role of PARPis in the treatment of tumors carrying mutations in DDR genes other than BRCA genes ( Table 2) . In comparison to the plethora of combination studies evaluating PARPi with chemotherapy, there are fewer trials evaluating PARPis as radiosensitizers. Recently, a trial evaluating low-dose radiotherapy with veliparib in patients with peritoneal carcinomatosis reported prolonged disease stabilization, particularly in patients with ovarian/fallopian tube cancer [30] . A phase I trial of olaparib with radiotherapy for inoperable breast cancer (NCT02227082) and a phase I study of olaparib and radiotherapy for stage II-III laryngeal and human papilloma virus-negative oropharyngeal squamous cell carcinomas (NCT02229656) are ongoing. A trial of radiotherapy, paclitaxel and carboplatin with or without veliparib in nonsmall cell lung cancer (stage III), is also currently ongoing (Table 2) .
Poly (ADP ribose) polymerase inhibitors with targeted agents
The most significant trial to date of this combinatorial approach has been the randomized phase II trial of olaparib with cediranib, an antiangiogenic agent with demonstrable activity against the vascular endothelial growth factor receptors 1, 2, and 3 [31] . The combination of these two oral agents significantly increased PFS and the overall response rate compared with olaparib alone in recurrent, platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer, with and without deleterious gBRCA1/2m. Median PFS, the primary endpoint of the trial, in the intent-to-treat population was 17.7 months (95% CI 14.7-not reached) with the combination of olaparib and cediranib compared with 9 months (95% CI 5.7-16.5, HR 0.42, 95% CI 0.23-0.76; P ¼ 0.005) for those treated with olaparib alone. There was a greater incidence of grade 3/4 adverse events, including hypertension, fatigue, and diarrhea in the combination arm [31] . Importantly, 77% of patients in the combination arm required a dose reduction compared with 27% in the olaparib arm [5, 31] . Intriguingly, the improvement in PFS Table 2 . was more marked in the BRCA wild-type patients receiving the combination than in those with gBRCAm [5, 31] . Overall survival data are awaited. Aberrations in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway, such as loss of PTEN or PI3K-activating mutations and sensitivity to PARP inhibition, have been controversial, though preliminary xenograft data have demonstrated improved antitumor activity for dual PARP and PI3K inhibition [5] . Other key regulators of DDR, such as ATM and ataxia telangiectasia Rad3-related kinases, are feasible targets given their role in DNA repair [32 && ]. It has also been reported that ATM or ataxia telangiectasia Rad3-related defects are synthetically lethal when combined with PARPi, suggesting a potential therapeutic strategy for tumor cells with these intrinsic deficiencies or with acquired DDR defects, and independent of gBRCAm status [32 && ]. Trials of these new combination approaches are in progress (Table 2) .
FUTURE DIRECTIONS
The successful development of PARPi for the treatment of gBRCAm ovarian cancer, as evidenced by the FDA approval of olaparib, is a welcome addition to the anticancer therapeutic armamentarium. There is extensive ongoing research exploring additional roles for PARPi in other tumors associated with mutations in the BRCA genes as well as those carrying defects in other genes involved in the DDR cascades. Combinatorial strategies with chemotherapy, radiation, and other targeted agents are being evaluated. The clinical benefit of combining PARPi with traditional cytotoxic agents will need to be balanced with the associated toxicities.
Recognition of the human immune system's capability to identify tumor-associated antigens and generate specific lymphocytes in response to them has been a crucial building block in the development of cancer immunotherapy. Specifically, the programmed death pathway-1 is postulated to suppress the cytotoxic immune response to many tumors that can occur in response to tumoral neoantigens [33] . The recently positive phase II trial of pembrolizumab, which reported a clinical benefit in tumors with mismatch repair deficiency [34] , would theoretically support the premise of synergic cytotoxic effect for the combination of PARPi and immunotherapy agents, with possibly nonoverlapping toxicities.
CONCLUSION
The approval of olaparib marks the creation of a new class of active anticancer agents and another step toward mainstreaming of precision medicine: tailoring of therapy to a specific subgroup of patients to obtain greater efficacy while limiting exposure to patients that will experience little benefit. Though the major development focus of these agents has been in gBRCAm-associated tumors, a growing understanding of other integral HR repair pathways will undoubtedly lead to evolving areas of therapeutic intervention. Significant progress in identifying additional predictive biomarkers will further improve patient selection, clinical benefit, inform combinations, and lead to a broader application of PARPi as anticancer therapies.
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